Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.

Haematologica 2020 Apr 23. Epub 2020 Apr 23.

Department of Pathology, University of Cambridge, Cambridge, UK;

Patients diagnosed with Anaplastic Large Cell Lymphoma (ALCL) are still treated with toxic multi-agent chemotherapy and as many as 25-50% of patients relapse. To understand disease pathology and to uncover novel targets for therapy, Whole-Exome Sequencing (WES) of Anaplastic Lymphoma Kinase (ALK)+ ALCL was performed as well as Gene-Set Enrichment Analysis. This revealed that the T-cell receptor (TCR) and Notch pathways were the most enriched in mutations. In particular, variant T349P of NOTCH1, which confers a growth advantage to cells in which it is expressed, was detected in 12% of ALK+ and ALK- ALCL patient samples. Furthermore, we demonstrate that NPM-ALK promotes NOTCH1 expression through binding of STAT3 upstream of NOTCH1. Moreover, inhibition of NOTCH1 with γ-secretase inhibitors (GSIs) or silencing by shRNA leads to apoptosis; co-treatment in vitro with the ALK inhibitor Crizotinib led to additive/synergistic anti-tumour activity suggesting this may be an appropriate combination therapy for future use in the circumvention of ALK inhibitor resistance. Indeed, Crizotinib-resistant and sensitive ALCL were equally sensitive to GSIs. In conclusion, we show a variant in the extracellular domain of NOTCH1 that provides a growth advantage to cells and confirm the suitability of the Notch pathway as a second-line druggable target in ALK+ ALCL.

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2019.238766DOI Listing
April 2020
5.868 Impact Factor

Publication Analysis

Top Keywords

cell lymphoma
8
large cell
8
alk+ alcl
8
advantage cells
8
alk inhibitor
8
anaplastic large
8
growth advantage
8
notch1
6
alcl
5
future circumvention
4
notch1 confers
4
t349p notch1
4
variant t349p
4
enriched mutations
4
mutations variant
4
circumvention alk
4
confers growth
4
therapy future
4
combination therapy
4
detected 12%
4

Similar Publications